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A B S T R A C T
Purpose
To identify diagnostic and prognostic markers of chronic graft-versus-host disease (cGVHD), the
major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT).
Patients and Methods
Using a quantitative proteomics approach, we compared pooled plasma samples obtained at
matched time points after HCT (median, 103 days) from 35 patients with cGVHD and 18 without
cGVHD (data are available via ProteomeXchange with identifier PXD002762). Of 105 proteins
showing at least a 1.25-fold difference in expression, 22 were selected on the basis of involvement
in relevant pathways and enzyme-linked immunosorbent assay availability. Chemokine (C-X-Cmotif)
ligand 9 (CXCL9) and suppression of tumorigenicity 2 (ST2) also were measured on the basis of
previously determined associations with GVHD. Concentrations of the four lead biomarkers were
measured at or after diagnosis in plasma from two independent verification cohorts (n = 391) to
determine their association with cGVHD. Their prognostic ability when measured at approximately
day +100 after HCT was evaluated in plasma of a second verification cohort (n = 172).
Results
Of 24 proteins measured in the first verification cohort, nine proteins were associated with cGVHD,
and only four (ST2, CXCL9, matrix metalloproteinase 3, and osteopontin) were necessary to com-
pose a four-biomarker panel with an area under the receiver operating characteristic curve (AUC) of
0.89 and significant correlation with cGVHD diagnosis, cGVHD severity, and nonrelapsemortality. In
a second verification cohort, this panel distinguished patients with cGVHD (AUC, 0.75), and finally,
the panel measured at day +100 could predict cGVHD occurring within the next 3 months with an
AUC of 0.67 and 0.79 without and with known clinical risk factors, respectively.
Conclusion
We conclude that the biomarker panel measured at diagnosis or day +100 after HCT may allow
patient stratification according to risk of cGVHD.
J Clin Oncol 34:2583-2590. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Chronic graft-versus-host disease (cGVHD) re-
mains the most common long-term complication
of allogeneic hematopoietic cell transplantation
(HCT), reportedly occurring in 30% to 70% of
patients surviving more than 100 days.1-3 It is also
the leading cause of nonrelapse mortality (NRM)
occurring more than 2 years after HCT for ma-
lignant disease.4,5 In 2014, the National Institutes
of Health (NIH) Consensus Development Project
on Criteria for Clinical Trials in cGVHD pub-
lished an updated series of articles to help stan-
dardize the clinical approach to treating these
patients, thereby promoting new interest in this
important post-transplantation complication
and motivating the development of well-defined
biomarkers for future use as an aid in clinical
trials.6-10
The development of acute graft-versus-host
disease (aGVHD) biomarkers11-14 has increased
interest in identifying biomarkers that provide
meaningful information for cGVHD. Several
studies have reported the discovery of cGVHD
biomarkers,9,15 but verification studies of these
biomarkers in independent cohorts are currently
lacking. Here, we used in-depth proteomic pro-
filing using gel-free, high-resolution tandemmass
spectrometry (MS/MS). Following the recent
recommendations from the NIH consensus,9 we
then verified the concentrations of individual
© 2016 by American Society of Clinical Oncology 2583
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candidate proteins in samples from an independent cohort of 211
HCT patients using high-throughput immunoassays. The leading
proteins were then tested in a second independent verification
cohort of 180 HCT patients. Finally, plasma protein concen-
trations were measured in samples collected on day +100 after
HCT from 172 of the 180 patients in verification cohort 2 to test
their potential as prognostic markers on the basis of their ability
to correctly identify patients who would subsequently develop
cGVHD.
PATIENTS AND METHODS
Three cohorts of patients were included in this study, as previously
described.16-18 This study was approved by the institutional review
boards of the participating institutions, and informed consent was
obtained from all patients or their legal guardians. Heparinized blood
samples were collected prospectively at the onset of manifestations in
patients with cGVHD or at matched time points in controls. Patients
in the verification 2 cohort also had samples drawn at approximately
day +100.
Concurrent controls were available in all three cohorts, and their
characteristics are listed in Table 1. For the discovery cohort and
verification cohort 1, controls were patients who did not have cGVHD. For
the verification cohort 2, where excess controls were available, controls
were selected to match patient cases on the basis of time since trans-
plantation, transplantation center, prior aGVHD, conditioning intensity,
and graft source. Chart review confirmed that controls did not develop
cGVHD in the 3 months after the sample was taken. See the Data Sup-
plement for additional information.
RESULTS
Discovery Study Using Quantitative Proteomics
Pooled plasma from 35 patients with cGVHD was labeled
with one isobaric tag for relative and absolute quantification
(iTRAQ) and compared with pooled plasma from 18 patients
without cGVHD, labeled with a different iTRAQ label (Appendix
Fig A1, online only). The characteristics of patients in the dis-
covery cohort are listed in Table 1. Patients in the cGVHD group
were older and more likely to have had prior aGVHD than the
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(n = 93) P
Age, years .03 .55 .44
Median 50 27 52 54 51 52
Range 6-67 1-66 19-79 22-72 21-78 20-71
Sex, No. (%) 1.00 .23 .50
Female 11 (31) 6 (33) 77 (43) 18 (55) 49 (56) 57 (61)
Male 24 (69) 12 (67) 101 (57) 15 (45) 38 (44) 36 (39)
Donor type and match, No. (%) .40 .06 .50
Matched sibling 29 (83) 17 (94) 66 (37) 18 (55) 38 (44) 36 (39)
Other‡ 6 (17) 1 (6) 112 (63) 15 (45) 49 (56) 57 (61)
Stem-cell source, No. (%) .11 .05 .62
PBSC 28 (80) 10 (56) 161 (90) 26 (79) 77 (89) 80 (86)
Other 7 (20) 8 (44) 17 (10) 7 (21) 10 (11) 13 (14)
Conditioning regimen intensity, No. (%) 1.00 .88 .83
Myeloablative 26 (74) 13 (72) 105 (59) 19 (58) 37 (43) 41 (44)
Nonmyeloablative 9 (26) 5 (28) 73 (41) 14 (42) 50 (57) 52 (56)
Prior acute GVHD, No. (%) , .001 .70 .24
Yes 18 (51) 0 (0) 135 (76) 24 (73) 38 (44) 49 (53)
No 17 (49) 18 (100) 43 (34) 9 (37) 49 (56) 44 (47)
Time post-HCT to cGVHD diagnosis, days NA NA NA
Median 119 NA 210 NA 203 NA
Range 56-352 NA 38-1757 NA 86-461 NA
Time post-HCT to sample acquisition, days .03 .84 .63
Median 103 102 391 369 236 192
Range 50-372 94-189 192-1,852 161-3,641 86-522 133-482
NIH global severity, No. (%) NA NA NA
Mild 2 (6) NA 13 (7) NA 15 (18) NA
Moderate 20 (57) NA 103 (58) NA 46 (55) NA
Severe 13 (37) NA 62 (35) NA 22 (27) NA
Corticosteroid use at time of sampling, No. (%) .29 , .001 , .001
Yes 4 (11) 0 (0) 108 (61) 2 (6) 51 (61) 22 (24)
No 31 (89) 18 (100) 70 (39) 31 (94) 36 (39) 71 (76)
Abbreviations: cGVHD, chronic graft-versus-host disease; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantations; NA, not applicable; NIH, National
Institutes of Health; PBSC, peripheral-blood stem cell.
*Matched for time since transplantation to sample collection, transplantation center, prior acute GVHD, conditioning intensity, and graft source from the U54multicenter
cohort (Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Minnesota, H. Lee Moffitt Cancer Center, Vanderbilt University Medical
Center, Roswell Park Cancer Institute, Washington University St Louis, and Cleveland Clinic).
†Eight patients missing data for prior acute GVHD, and four patients missing data for NIH severity.
‡Other: There were only four cord blood cell transplantations among the patients and none among the controls.
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controls without cGVHD. Otherwise, there were no statistically
significant differences between the patients with cGVHD and
without cGVHD according to sex, donor and HLA type, graft
source, or conditioning intensity. Of note, samples were selected
so that patients had minimal to no corticosteroid immuno-
suppression at the time of sampling in both patients with
cGVHD and controls. Samples were collected at similar times for
both patients with cGVHD and controls, with a less extended
range for controls because the blood collection from controls
occurred at regular visits, around day +100 and day +180 after
HCT. Samples were thus obtained at a median of 103 days (range,
50 to 372 days) after HCT in the cGVHD group compared with
102 days (range, 94 to 189 days) after HCT in the control group
(P = .03).
iTRAQ labels allow for comparison of relative concentra-
tions of proteins between groups (see Patients and Methods).
Overall, 1,998 proteins were identified and quantified, and 105 of
these proteins were differentially expressed by at least a 1.25-fold
difference that distinguished cGVHD patients from patients
without cGVHD at the time of sampling (Data Supplement).
Antibodies suitable for enzyme-linked immunosorbent assays
were available for 22 of these proteins (Data Supplement), and
CXCL9 and ST2 also were considered for validation based
on previously noted associations with cGVHD or refractory
GVHD.14,18
Biomarker Panel Development With Verification
Cohort 1
Wemeasured the concentrations of the 24 proteins mentioned
earlier in samples from cohort 1, which consisted of 178 HCT
patients with cGVHD and 33 HCT controls without cGVHD. The
patient and GVHD characteristics for the two groups are listed in
Table 1. Patient sex and median age at the time of transplantation
were similar between the two groups. There was a trend toward
over-representation of unrelated donors in the cGVHD group. As
expected, the use of peripheral-blood stem cells (PBSCs) was a risk
factor for cGVHD, whereas the use of full-intensity conditioning
was not. The incidence of prior aGVHD was similar in both
groups. According to the NIH global severity score, 7% of the
patients had mild cGVHD, 58% had moderate cGVHD, and 35%
had severe cGVHD. Plasma samples were collected at similar times
from both cGVHD patients and controls, at a median of 391 days
(range, 192 to 1,852 days) after HCT in the cGVHD group
compared with 369 days (range, 161 to 3,641 days) after HCT in
the control group (P = .84). Unlike the discovery cohort, 61% of
the patients with cGVHD were receiving corticosteroid treatment
at the time of sampling, compared with 6% of control patients
(P , .001).
To create the biomarker panel, logistic regression was used to
evaluate associations between cGVHD and biomarkers after log
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Fig 1. (A) Receiver operating characteristic
(ROC) curves for the best single biomarker
and the combination model in verification
cohort 1. ROC curves for the best single
biomarker (ST2; area under the curve [AUC],
0.83) and the combinationmodel (AUC, 0.89)
comparing patientswith chronic graft-versus-
host disease (cGVHD; n = 178) and time-
matched controls without cGVHD (n = 33).
AUC values are reported from multivariable
models. (B) Increased biomarker panel levels
are associated with increased cGVHD se-
verity in verification cohort 1.Median value of
the four-biomarker panel from controls
(n = 33), patientswithmild tomoderate (Mod)
cGVHD (n = 116), and patients with severe
cGVHD (n = 62) in verification cohort 1. Data
are illustrated as box and whisker plots, with
the whiskers indicating the 90th and 10th
percentiles. P values compare controls ver-
sus patients with mild to moderate cGVHD,
and patients with mild to moderate cGVHD
versus those with severe cGVHD, according
to Wilcoxon two-sample tests. (C) Non-
relapse mortality (NRM) stratified by the
biomarker panel in verification cohort 1. The
cumulative incidence of NRM is plotted,
divided according to the median value of
the biomarker panel among patients with
cGVHD. The NRM at 48 months was 5%
(95% CI, 1% to 9%) for the group less than
themedian value and 36% (95%CI, 19% to
53%) for the group greater than the median
value (P = .002; adjusted for age, sex, donor
[matched sibling v others], stem-cell source
[peripheral-blood stem cells v others], con-
ditioning intensity [myeloablative v others],
prior acute GVHD, and time from hema-
topoietic cell transplantation to sample
collection).
www.jco.org © 2016 by American Society of Clinical Oncology 2585
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adjusted for the following seven clinical variables: age, sex, donor
(matched sibling v others), stem-cell source (PBSC v others),
conditioning intensity (myeloablative v others), prior aGVHD, and
time from HCT to sample collection. Notably, only donor type
(P = .03) and PBSCs as the stem-cell source (P = .01) were sig-
nificant in multivariable analysis. Of the 24 proteins tested, nine
were associated with cGVHD with a P , .05 (Table 2). To de-
termine the best combination model, we used unadjusted for-
ward selection with a P = .05 significance threshold using these
nine markers, confirmed by backward selection. The selection
procedure identified four proteins, ST2, MMP3, CXCL9, and
OPN, for inclusion in the combination panel. The other five
proteins were not included in the panel because they did not show
an additional effect in forward and backward selection models
(Table 2). We then generated receiver operating characteristic
curves for the best single biomarker and the combination model.
The area under the curve (AUC) for the four-biomarker panel was
0.89, whereas the AUC for ST2 was 0.83 (Fig 1A). To better define
the potential clinical utility of the four identified proteins, we also
tested, in multivariable models with and without clinical cova-
riates, the association of biomarker levels with cGVHD in this
cohort (Table 2).
Biomarker Panel and cGVHD Severity and NRM in
Verification Cohort 1
We next evaluated whether the biomarker panel was associ-
ated with cGVHD severity. Few patients had mild cGVHD, and
thus, these patients were combined with those who presented with
moderate cGVHD. Using Wilcoxon two-sample tests, we com-
pared the biomarker panel (defined using the following equation:
3.23 3 log10 ST2 + 1.81 3 log10 CXCL9 + 1.64 3 log10 MMP3 +
1.583 log10 OPN) between groups with different cGVHD severity
(none, mild or moderate, and severe). The severity of cGVHD was
correlated with the biomarker panel (P , .001 comparing none
with any cGVHD, and P = .03 comparing mild or moderate with
severe cGVHD [unadjusted], Fig 1B). In regression analysis with
adjustment for clinical variables, P = .006 for mild or moderate
versus severe cGVHD.
NRM was compared between groups with high versus low
biomarker levels using a cutoff of the median value of the
biomarker panel (median value obtained from the formula given
earlier) among patients with cGVHD. Patients with cGVHD and
biomarker panel levels greater than the median had higher
NRM, with a hazard ratio of 7.0 (95% CI, 2.0 to 24.8) and
P = .003 after adjustment for the previously mentioned clinical
characteristics, compared with patients with cGVHD with lower
biomarker panel levels (Fig 1C). Finally, because the cohort
consisted entirely of patients with multiorgan involvement, the
biomarker panel was not associated with any specific target
organ (Data Supplement).
Verification Cohort 2 From a Prospective Multicenter
Consortium
We then sought to verify the four-biomarker panel further in
a second independent cohort of 180 patients from the Chronic
GVHD Consortium. Patient and GVHD characteristics in the first
and second cohorts are listed in Table 1 and are similar because
patients had been matched accordingly. However, compared with
the first cohort, fewer patients in this cohort received full-intensity
conditioning and fewer patients had previously experienced
aGVHD. Cohort 2 also included more patients with mild cGVHD
(18% v 7% in cohort 1) and fewer patients with severe cGVHD
(27% v 35% in cohort 1) according to the NIH global severity
score. The median day of sample collection was earlier than in the
previous cohort, at approximately 8 months, and did not differ
between the cGVHD and control groups. Similar to verification
cohort 1, 61% of the patients with cGVHD were being treated with
corticosteroids at time of sampling, but unlike verification cohort
1, 24% of the controls also were receiving corticosteroid treatment
at the time of sampling (P , .001), which was adjusted for in the
analysis.
Three of the four biomarkers included in the panel (ST2,
CXCL9, andMMP3) were confirmed to be associated with cGVHD
in this cohort, whereas OPN was not. The biomarker panel in-
cluding all four markers had an AUC of 0.75 in this cohort, whereas
the AUC for ST2 was 0.67 (P , .001 and P , .001, respectively;
Table 3 and Fig 2A). The combination of biomarkers with clinical
covariates increased the AUC to 0.82 (P , .001; Table 3).
Table 2. Association of Biomarker Levels With cGVHD in Verification Cohort 1
(178 patients and 33 controls)
Model OR* (95% CI) P AUC†
Single biomarkers
ST2 104 (17 to 623) , .001 0.83
MMP3 11.6 (4.1 to 33) , .001 0.79
TNFRSF10C 68.0 (7.5 to 617) , .001 0.72
OPN 11.7 (3.8 to 36) , .001 0.71
SELP 22.8 (2.3 to 227) .005 0.66
CKIT 0.06 (0.007 to 0.45) .004 0.65
COMP 9.6 (1.7 to 53) .006 0.64
CXCL9 3.5 (1.2 to 10) .02 0.63
CD146 39.5 (1.4 to 999) .03 0.62
Best combination of
biomarkers
ST2 25.4 (3.6 to 180) , .001 0.89
CXCL9 6.1 (1.5 to 24)
MMP3 5.2 (1.5 to 18)
OPN 4.8 (1.2 to 19)
Single biomarkers with
clinical covariates‡
ST2 124 (18 to 857) , .001 0.85
MMP3 11.7 (3.8 to 36) , .001 0.80
TRAILR3 91.9 (8.2 to 999+) , .001 0.77
OPN 14.5 (4.1 to 52) , .001 0.79
SELP 31.5 (2.8 to 357) .003 0.73
CKIT 0.06 (0.006 to 0.54) .008 0.73
COMP 25.4 (3.2 to 200) .008 0.74
CXCL9 4.5 (1.4 to 14.3) .009 0.71
CD146 47.2 (1.3 to 999) .03 0.70
Best combination of biomarkers
with clinical covariates‡
ST2 70.2 (6.5 to 761) , .001 0.92
CXCL9 26.9 (3.9 to 186)
MMP3 7.9 (2.0 to 30.9)
OPN 11.9 (2.1 to 68.5)
Abbreviations: AUC, area under the curve; cGVHD, chronic graft-versus-host
disease; OR, odds ratio.
*OR per log increase in biomarker, estimated using logistic regression.
†AUC calculated from logistic regression; includes clinical covariates in model
where indicated.
‡AUC with clinical covariates only: 0.66.
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In this cohort, the biomarker panel was not significantly
associated with a difference in severity of cGVHD (P = .40; Fig 2B).
NRM could not be evaluated because only eight patients with
cGVHD experienced NRM events during the period of observa-
tion. Previously reported biomarkers for both aGVHD and
cGVHD have been shown to decrease after initiation of cortico-
steroid treatment,19,20 and therefore, we analyzed the effect of
corticosteroid treatment and prior aGVHD on the ability of the
biomarker panel to distinguish patients with cGVHD from those
without cGVHD. The biomarker panel showed better performance
when comparing patients who were not receiving treatment with
corticosteroids (Fig 2C) and did not have prior aGVHD (Fig 2D).
The difference in corticosteroid use in the controls is a result of the
cohorts from which they were derived. Cohort 2 controls were
a median of approximately 6.5 months after transplantation. Their
corticosteroid use likely was from residual treatment of aGVHD. In
contrast, cohort 1 controls were approximately 12 months after
transplantation, explaining the lower corticosteroid exposure at the
time of sampling. We reviewed the charts of all controls to confirm
that none had active aGVHD or cGVHD at the time of sampling or
within the subsequent 3 months. We also analyzed the influence of
calcineurin inhibitors (CNIs) on biomarker expression in cohort 2
and found that the fold-difference in levels for patients on CNI
versus those not on CNI was significantly decreased only for
CXCL9 (0.67-fold, P = .03), whereas levels were not decreased for
ST2, MMP3, and OPN. Because CNIs are also used to treat GVHD,
we analyzed the effect of CNI treatment on the ability of the
biomarker panel to distinguish patients with cGVHD from those
without and found that the panel showed better performance when
comparing patients who were not receiving CNIs with those who
were receiving CNIs (AUC, 0.92; P , .001 v AUC, 0.71; P = .002,
respectively). This same analysis is not meaningful in cohort 1
because only 27% of controls were on CNIs, whereas 67% of the
patient cases were on CNIs at time of sample draw, consistent with
the fact that the samples were drawn a median of 1 year after HCT.
Similar to cohort 1, cohort 2 consisted entirely of patients with
multiorgan involvement, and thus, the biomarker panel was not
associated with involvement of any specific target organ (Data
Supplement).
Day +100 Post-HCT Samples From Verification Cohort
2 and Association With Future cGVHD Occurrence
We next measured the plasma concentrations of the four
biomarkers on approximately day +100 after HCT in 172 patients
from cohort 2 for whom day +100 samples were available to
evaluate their potential prognostic value before the diagnosis of
cGVHD. The biomarker panel (particularly CXCL9 and ST2) at
day +100 after transplantation was significantly associated with
subsequent development of cGVHD within 3 months (median
time from sample to diagnosis of 51 days; range, 14 to 91 days),
with an AUC of 0.67 (P = .009; Table 4). The combination of
biomarkers with clinical covariates increased the AUC to 0.79
(P = .001; Table 4). In this cohort, the AUC with the clinical
covariates only was 0.72, and the AUC with aGVHD status only
was 0.60 (data not shown). Interestingly, although corticoste-
roid use at day +100 was correlated with prior aGVHD, as
expected, it was not prognostic for the future development of
cGVHD (AUC, 0.52).
DISCUSSION
The discovery of valid and reproducible biomarkers for cGVHD
remains a significant challenge. Compared with aGVHD, cGVHD
is clinically more heterogeneous and can involve many more target
organs, often simultaneously. First, a major strength of this study
was our ability to reproduce a correlation of the four-biomarker
panel with cGVHD in a second verification cohort that included
samples from eight different sites, which meets the current pre-
ferred requirement for the identification of biomarkers according
to the 2014 NIH biomarker consensus.9 Unfortunately, the as-
sociation of biomarkers with cGVHD severity and NRM in the first
verification cohort was not seen in the second verification cohort,
possibly because of the number of controls on corticosteroids at the
time of sampling in cohort 2 as compared with that in cohort 1,
which could mask the biomarker levels, and the low numbers of
NRM events, respectively. Second, the fact that a biomarker panel
at day +100 after HCTwas associated with subsequent cGVHD and
remained elevated at the time of onset suggests that serial mea-
surements from day +100 after HCT and beyond may identify
high-risk patients for earlier intervention. For example, patients at
high risk for cGVHD could be monitored more closely or even
receive pre-emptive treatment designed to avert onset or at least
minimize cGVHD severity.
In addition, our discovery approach has highlighted some
interesting biologic pathways that may represent novel therapeutic
Table 3. Association of Biomarker Levels With cGVHD in Verification Cohort 2
(87 patients and 93 controls)
Model OR* (95% CI) P AUC†
Single biomarkers
ST2 4.77 (2.0 to 11.6) , .001 0.67
CXCL9 2.69 (1.5 to 5.0) , .001 0.64
MMP3 3.36 (1.7 to 6.7) .003 0.66
OPN 1.31 (0.4 to 4.6) .66 0.53
Combination of biomarkers
ST2 4.29 (1.5 to 12.2) , .001 0.75
CXCL9 3.48 (1.8 to 6.9)
MMP3 2.45 (1.1 to 5.5)
OPN 0.35 (0.1 to 1.6)
Single biomarkers with clinical
covariates‡
ST2 3.76 (1.2 to 11.5) .02 0.76
CXCL9 3.81 (1.9 to 7.7) , .001 0.79
MMP3 1.97 (0.9 to 4.4) .09 0.76
OPN 0.99 (0.2 to 4.2) .98 0.74
Combination of biomarkers
with clinical covariates‡
ST2 4.19 (1.2 to 14.4) , .001 0.82
CXCL9 4.47 (2.1 to 9.5)
MMP3 1.69 (0.7 to 4.0)
OPN 0.40 (0.1 to 2.0)
Abbreviations: AUC, area under the curve; cGVHD, chronic graft-versus-host
disease; OR, odds ratio.
*OR per log increase in biomarker, estimated using logistic regression.
†AUC calculated from logistic regression; includes clinical covariates in model
where indicated
‡AUC with clinical covariates only: 0.74.
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avenues relevant to the three proteins found to be increased in both
verification cohorts. CXCL9 is a T-helper type 1 chemokine that
has been shown to attract CXCR3+CD4+ T cells in target organs
and can be detected in the blood.18,21,22 Some therapies used for
aGVHD, such as bortezomib, inhibit T-cell chemotactic move-
ments, decrease CXCR3 expression and CXCL9 secretion,23 and
may prevent GVHD.24,25 Other CXCL9 and CXCR3 inhibitors are
under development. Soluble ST2 is secreted by intestinal cells
during aGVHD in experimental models, and ST2 blockade reduces
the numbers of these cells.26,27 Further experiments are needed to
determine the effects of ST2 blockade in cGVHD models. MMPs
are prominent contributors tomicroenvironmental signals because
these proteolytic enzymes degrade structural components of the
extracellular matrix, permitting tissue remodeling.28 MMP3, in
particular, has been shown to promote the epithelial-mesenchymal
transition, potentially leading to tissue fibrosis.29 Opposite to the
three other markers that were found at high levels early in the
cGVHD course, MMP3 plasma concentrations seemed to increase
over time from cGVHD onset (Appendix Fig A2, online only),
potentially reflecting matrix remodeling in response to fibrosis. We
could not explore the differences between lichenoid and sclerotic
forms of cGVHD because the NIH skin score combines these two
types of manifestation, and thus, a clear distinction is not possible.
Notably, no other MMPs were found to be differentially regulated
in this proteomics experiment. MMP3 inhibitors are expected to be
available in the near future.30
Several limitations to the current study should be noted.
First, although our approach used tandem MS/MS and can be
considered unbiased, tandem MS/MS has a technical limitation
in the detection of low-abundance proteins, particularly if trypsin
digestion is applied at the beginning of the workflow (before
fractionation), as in our iTRAQ experiments.31 This was not true
for our previous approach using the Intact Protein Analysis
System with trypsin digestion occurring after extensive frac-
tionation.12 Second, the timing of sample acquisition for bio-
marker assessment is critical. Once immunosuppression has been
initiated, the biomarker pattern may change, as has been ob-
served with B-cell activating factor plasma concentrations in
patients treated with corticosteroids.19 Newly diagnosed and
established patients with cGVHDwere studied together, although
the pathologic processes culminating in a new diagnosis may
differ from those present in established disease. Similarly, all
phenotypes of cGVHD were grouped together into cGVHD,
although the organ involvement and prognosis of cGVHD are
heterogeneous. If different cGVHD phenotypes reflect different
underlying biology, this aggregation may impede identification of
important biomarkers. The biomarker panel performed better
when applied to similar groups of patients and controls who were
not receiving corticosteroid treatment at the time of sample
collection. Third, the relevance of the AUCs with clinical
covariates in the verification cohort 2 should be interpreted with
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Fig 2. (A) Receiver operating characteristic (ROC)
curves for the best single biomarker and the com-
bination model in verification cohort 2. ROC curves
for the best single biomarker (ST2; area under the
curve [AUC], 0.67) and thecombinationmodel (AUC,
0.75) comparing patients with chronic graft-versus-
host disease (cGVHD; n = 87) and time-matched
controls without cGVHD (n = 93). AUC values are
reported from multivariable models. (B) Association
between biomarker panel and cGVHD severity in
verification cohort 2. Median value of the four-
biomarker panel from controls (n = 93), patientswith
mild to moderate (Mod) cGVHD (n = 61), and pa-
tients with severe cGVHD (n = 22) in verification
cohort 2. Data are illustrated as box and whisker
plots, with thewhiskers indicating the 90th and 10th
percentiles. P values compare controls versus pa-
tients with mild to moderate cGVHD and patients
with mild to moderate cGVHD versus those with
severe cGVHD, according to Wilcoxon two-sample
tests. (C and D) The utility of the biomarker panel is
influenced by immunosuppression therapy and prior
acute graft-versus-host disease (GVHD). (C) ROC
curves for the combination model in verification
cohort 2 comparingpatientsonprednisoneat timeof
samplingwith cGVHD (n = 51) versus time-matched
controls on prednisone without cGVHD (n = 22;
AUC, 0.65) and comparing patients not on predni-
sone at time of sampling with cGVHD (n = 36)
versus time-matched controls not on prednisone
without cGVHD (n = 71; AUC, 0.77). (D) ROCcurves
for the combinationmodel in the verification cohort 2
comparing patientswith cGVHDandwith prior acute
GVHD (n = 38) versus time-matched controls
without cGVHD but with prior acute GVHD (n = 49;
AUC, 0.72) and comparing patients with cGVHD but
without prior acute GVHD (n = 49) versus time-
matched controls without cGVHD and without prior
acute GVHD (n = 44; AUC, 0.79).
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some covariates. The same consideration is applicable to the day
+100 analysis that aimed to determine whether the biomarker
panel could be used to anticipate the development of cGVHD
before the clinical onset of the disease. Specifically, as a result of
our case-control design, we cannot estimate the positive pre-
dictive value of the biomarker factors as prognostic factors for
cGVHD because they would be used in an actual clinical setting
of unselected patients. Thus, this biomarker panel should be
evaluated in a prospective study with serial collection of
samples ideally starting at day +100 after HCT or even earlier
(day +80) before it is accepted for risk stratification in clinical
trials.
We conclude that the combination of plasma concentrations
of four proteins might represent a biomarker panel for noninvasive
identification of cGVHD as verified in two independent cohorts.
The biomarker panel was associated with cGVHD severity and
prediction of NRM in one cohort. Importantly, when measured as
early as day +100 after HCT, the biomarker panel in association
with key clinical covariates was a good predictor of the risk of
cGVHD occurrence in the next 3 months. Future directions should
include prospective and serial evaluations of the panel to define its
clinical use as a prognostic biomarker panel in an unselected
population.
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Fig A1. Isobaric tags for relative and absolute quantification (iTRAQ) proteomics
workflow in the chronic graft-versus-host disease (cGVHD) study. Three pools of
plasma were compared in the same proteomic experiment. Pool 1 contained
plasma from 17 patients with de novo cGVHD available at the onset of clinical
symptoms, pool 2 contained plasma from 18 patients without cGVHD (collected at
similar time points as cGVHD samples), and pool 3 contained plasma from
18 patients with progressive cGVHD. The three pooled plasmas were then in-
dividually immunodepleted of the 20 common hyperabundant proteins followed by
enzymatic digestion with trypsin and protein extraction. Each pool was then
labeled for quantification by iTRAQ (32) as follows: de novo cGVHD with iTRAQ
114, control with iTRAQ 115, and progressive cGVHD with iTRAQ 116. All the

















Fig A2. Plasma MMP3 concentrations increase from time of chronic graft-
versus-host disease (cGVHD) onset in patients with cGVHD in verification cohort 1
(n = 178). Dashed line is estimated fit from linear regression model (P = .009).
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